Abstract
Thyroid stimulating hormone (TSH) receptor (TSHR) antibodies (TRAb) are the hallmarks
in serological diagnosis of Graves’ disease (GD, autoimmune hyperthyroidism). In the
1980s, the first generation liquid-phase TRAb assay with detergent solubilized porcine
TSHR was introduced into routine thyroid serology and proved to be highly specific
for GD, albeit with moderate sensitivity. In the 1990s, second generation solid-phase
TRAb assays with immobilized porcine or recombinant human TSHR became available, and
were clearly more sensitive for Graves’ disease without loss of specificity. Recently,
third generation TRAb assays have been developed, in which the human thyroid stimulating
monoclonal antibody M22 replaces bovine TSH as the competing reagent for TRAb binding
to TSHR. Again, an improvement in functional sensitivity was reported for this latest
assay generation. To investigate the analytical (aas) and functional assay sensitivity
(fas) over 3 generations of TRAb assays, pooled serum samples from patients with GD
were measured 10-fold in different assay lots over a few months. The 20% inter-assay
coefficients of variation (CV) were calculated and compared taking into account the
different calibrations of the assay generations. The fas continuously increased from
about 8 U/l of MRC B65/122 in liquid phase TRAb assays, to about 1.0 IU/l (NIBSC 90/672)
in TSH based solid phase TRAb assays and to about 0.3 IU/l (NIBSC 90/672) in the M22
based TRAb assay finally. In conclusion, the fas of TRAb measurements has been improved
continuously over the last 3 decades.
References
- 1
Furmaniak J, Rees Smith B.
Autoimmunity.
1990;
7
63-80
- 2
Jacobson DL, Gange SJ, Rose NR, Graham NM.
Clin Immunol Immunopathol.
1997;
84
223-243
- 3
Weetman AP.
Horm Metab Res.
2009;
41
421-425
- 4
Tanda ML, Piantanida E, Lai A, Lombardi V, Dalle Mule I, Liparulo L, Pariani N, Bartalena L.
Horm Metab Res.
2009;
41
436-442
- 5
Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M.
Horm Metab Res.
2009;
41
456-464
- 6
Rees Smith B, Sanders J, Evans M, Tagami T, Furmaniak J.
Horm Metab Res.
2009;
41
448-455
- 7
Rees Smith B, Hall R.
Lancet.
1974;
2
427-431
- 8
Shewring G, Rees Smith B.
Clin Endocrinol (Oxf).
1982;
17
409-417
- 9
Kakinuma A, Morimoto I, Kuroda T, Fujihira T, Eto S, McLachlan SM, Rapoport B.
Thyroid.
1999;
9
849-855
- 10
Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S,
Weglöhner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K,
Vassart G, Usadel KH.
J Clin Endocrinol Metab.
1999;
84
90-97
- 11
Sanders J, Oda Y, Roberts S, Kiddie A, Richards T, Bolton J, McGrath V, Walters S,
Jaskolski D, Furmaniak J, Rees Smith B.
J Clin Endocrinol Metab.
1999;
84
3797-3802
- 12
Bolton J, Sanders J, Oda Y, Chapman C, Konno R, Furmaniak J, Rees Smith B.
Clin Chem.
1999;
45
2285-2287
- 13
Sanders J, Evans M, Premawardhana LD, Depraetere H, Jeffreys J, Richards T, Furmaniak J,
Rees Smith B.
Lancet.
2003;
362
126-128
- 14
Rees Smith B, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P,
Sanders J, Furmaniak J.
Thyroid.
2004;
14
830-835
- 15
Zöphel K, Roggenbuck D, von Landenberg P, Wunderlich G, Grüning T, Kotzerke J, Lackner KJ,
Rees Smith B.
Horm Metab Res.
2010;
42
65-69
- 16
Liu C, Hermsen D, Domberg J, Graeber C, Hautzel H, Duan Y, Xu KF, Liu CP, Mao XD,
Cupisti K, Scherbaum WA, Schott M.
Horm Metab Res.
2008;
40
79-83
- 17
Zöphel K, von Landenberg P, Roggenbuck D, Wunderlich G, Kotzerke J, Lackner KJ.
Clin Lab.
2008;
54
1-8
- 18
Kamijo K.
Endocr J.
2005;
52
525-529
- 19
Kamijo K.
Endocr J.
2003;
50
113-116
- 20
Hirooka Y, Li C, Takagi J, Gotoh M, Habus S, Yasaka-Nomura T, Ishihara R, Nakasone Y,
Nakamura R, Otake K, Nogimori T, Ishizuki Y.
Int J Clin Pharm Res.
2004;
24
111-116
- 21
Schott M, Hermsen D, Broecker-Preuss M, Casati M, Mas JC, Eckstein A, Gassner D, Golla R,
Graeber C, van Helden J, Inomata K, Jarausch J, Kratzsch J, Miyazaki N, Moreno MA,
Murakami T, Roth HJ, Stock W, Noh JY, Scherbaum WA, Mann K.
Clin Endocrinol (Oxf).
2009;
71
566-573
- 22
Hermsen D, Eckstein A, Schinner S, Willenberg HS, Thiel A, Scherbaum WA, Schott M.
Horm Metab Res.
2010;
42
295-297
1 KZ und DR contributed equally to this study.
Correspondence
K. ZöphelMD
Department of Nuclear
Medicine
Carl Gustav Carus Medical
School
University of Technology
Dresden
Fetscherstraße 74
01307 Dresden
Germany
Phone: +49/351/458 13879
Fax: +49/351/458 5347
Email: klaus.zoephel@uniklinikum-dresden.de